Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 90 results for menopause

  1. Depression in adults (QS8)

    This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.

  2. Bisphosphonates for treating osteoporosis (TA464)

    Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.

  3. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.

  4. Proov Confirm for ovulation confirmation (MIB322)

    NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .

  5. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

  6. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

  7. Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause (IPG738)

    We have moved interventional procedures guidance 738 to become HealthTech guidance 640. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  8. Obeticholic acid for treating primary biliary cholangitis (TA443)

    Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.

  9. Gout: diagnosis and management (NG219)

    This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.

  10. Colli-Pee for first void urine collection (MIB273)

    NICE has developed a medtech innovation briefing (MIB) on Colli-Pee for first void urine collection .

  11. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  12. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at high risk

    The medicine NICE recommends for most women who have been through the menopause is called anastrozole. However, this may not be suitable...

  13. Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over (TA1101)

    Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.

  14. Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)

    This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.

  15. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at moderately increased risk

    The medicine NICE recommends for most women who have been through the menopause is called anastrozole. However, this may not be suitable...